Clinical trial Recruiting at 1 site Interventional Ages 18 and up

Effect of early antibiotics on patients with out-of-hospital cardiac arrest

Official title: Impact of Early Antibiotics on Non-Traumatic Out of Hospital Cardiac Arrest (OHCA)

Run by Hamad Medical Corporation · NCT05914779 · Data updated 2026-11-12

This study is testing if not giving antibiotics to adults who have had a cardiac arrest outside the hospital is just as safe and effective as giving them early antibiotic treatment.

More Out-Of-Hospital Cardiac Arrest trials

Quick facts

Study typeInterventional
Ages18 Years and up
SexAll
Enrollment1000 (estimated)
SponsorHamad Medical Corporation
Industry-sponsored
Drugs / interventionsprednisone
Locations1 site (Doha, Baladiyat ad Dawhah)
StatusRecruiting
StartedMarch 1, 2023
Main results expectedDecember 31, 2025
Study endsDecember 31, 2025
Registry record updatedApril 3, 2025
Trial IDNCT05914779 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates are adults over 18 years old who have experienced out-of-hospital cardiac arrest and have a very low likelihood of infection.

Probably not a fit

Patients with clear evidence of infection or those who have received antibiotics within the past week will not benefit from this study.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical trial aims to evaluate whether not administering antibiotics to out-of-hospital cardiac arrest (OHCA) patients with a very low likelihood of infection is as effective as providing early antibiotic treatment. It will compare 28-day all-cause mortality rates, incidence of proven infections, and lengths of ICU and overall hospital stays between the two groups. The study will involve adults over 18 years old who present to the emergency department after OHCA. Participants will be randomly assigned to receive either no antibiotics or early antibiotic therapy.

Why it matters

Potential benefit: If successful, this study could help refine treatment protocols for OHCA patients, potentially reducing unnecessary antibiotic use.

How similar studies have gone: Other studies have explored antibiotic use in similar contexts, but this specific approach is relatively novel.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* ● Adults aged \>18 years, presenting to HGH ED after out-of-hospital cardiac arrest

  * Patients with low likelihood of infection as per the definitions provided above
  * Ability to obtain informed consent from the subjects or their next of kin/family member/legal surrogate in case of incapacitation due to sedation, mechanical ventilation, etc. In case the next of kin is not available, an independent physician who is not a part of the investigative team will complete and sign the checklist as per HMC Policy "RES 11026\_Appendix 6.5". (see section 4.1.3 for details) A member of the investigative team and a witness will also sign this form before the potential subject is enrolled in the study.

Exclusion Criteria:

* Patients who have clear evidence of infection, as defined by criteria for the study.

  * Patients who have received antibiotics within the last 1 week prior to admission.
  * Patients with malignancy, except those who have been cured or in complete remission.
  * Females with known pregnancy.
  * Known immunocompromised states (including HIV/AIDS, transplant recipients on immunosuppressant drugs, long-term \[\> 3 weeks of prednisone \>5mg/day equivalent\] steroid therapy).
  * Patients on immunologic disease modifying agents (commonly known as "biologics")
  * Patients considered "brain-dead" or "vegetative state"
  * Patients transferred from another hospital, long term care facility or institution
  * Neutropenia (total WBC \<1,500/mm3 or absolute neutrophil count of \<1,000/mm3)

Where it's running

  • Hamad Medical Corporation
    Doha, Baladiyat ad Dawhah, Qatar
    Recruiting

Study contacts

  • Principal investigator: Adeel A Butt, MBBS, MS — Hamad Medical Corporation
  • Study coordinator: Adeel A Butt, MBBS, MS
  • Email: aabutt@hamad.qa
  • Phone: +97433311228

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.